Oragenics IncNYSE American:OGEN
- LAST PRICE3.2893
- TODAY'S CHANGE (%)0.3693 (12.6473%)
- Bid / Lots3.0200/ 1
- Ask / Lots3.2800/ 1
- Open / Previous Close2.9900 / 2.9200
- Day Range
- 52 Week Range
- Volume41,522
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OGEN |
|---|---|---|
| 10:12 ET | 818 | 3 |
| 10:26 ET | 100 | 2.98 |
| 10:57 ET | 100 | 3.008 |
| 11:00 ET | 100 | 3.0199 |
| 11:20 ET | 1100 | 3.02 |
| 11:24 ET | 3198 | 3.04 |
| 11:26 ET | 1515 | 3.1034 |
| 11:31 ET | 417 | 3.13 |
| 11:33 ET | 200 | 3.12 |
| 11:36 ET | 558 | 3.14 |
| 11:44 ET | 1400 | 3.11 |
| 12:25 ET | 500 | 3.14 |
| 12:38 ET | 100 | 3.14 |
| 01:08 ET | 600 | 3.1599 |
| 01:42 ET | 2299 | 3.17 |
| 01:44 ET | 145 | 3.1993 |
| 01:55 ET | 1342 | 3.2 |
| 01:57 ET | 264 | 3.2 |
| 02:02 ET | 422 | 3.2174 |
| 02:04 ET | 1000 | 3.205 |
| 02:13 ET | 1300 | 3.205 |
| 02:15 ET | 100 | 3.22 |
| 02:36 ET | 500 | 3.2499 |
| 03:03 ET | 784 | 3.24 |
| 03:05 ET | 1516 | 3.2401 |
| 03:07 ET | 287 | 3.3 |
| 03:14 ET | 2019 | 3.29 |
| 03:16 ET | 1000 | 3.2547 |
| 03:18 ET | 2100 | 3.2547 |
| 03:41 ET | 1000 | 3.2997 |
| 03:43 ET | 2390 | 3.275 |
| 03:45 ET | 3363 | 3.34 |
| 03:48 ET | 3688 | 3.355 |
| 03:54 ET | 600 | 3.3 |
| 03:59 ET | 0 | 3.2893 |
Mar 29, 2023
Oragenics to Participate in the World Vaccine Congress Washington, from 11:45AM ET on Wednesday Mar 29, 2023 by Business Wire
11:45AM ET on Wednesday Mar 29, 2023 by Business Wire
Mar 14, 2023
BRIEF-Oragenics Announces Positive Results In Several Lantibiotics Compounds Against Mrsa And Vre, from 8:45AM ET on Tuesday Mar 14, 2023 by Thomson Reuters
8:45AM ET on Tuesday Mar 14, 2023 by Thomson ReutersOragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE, from 8:30AM ET on Tuesday Mar 14, 2023 by Business Wire
8:30AM ET on Tuesday Mar 14, 2023 by Business Wire
Mar 8, 2023
Oragenics Names Janet Huffman CFO, from 12:16PM ET on Wednesday Mar 08, 2023 by MT Newswires
12:16PM ET on Wednesday Mar 08, 2023 by MT NewswiresBRIEF-Oragenics Appoints Janet Huffman As Chief Financial Officer , from 9:15AM ET on Wednesday Mar 08, 2023 by Thomson Reuters
9:15AM ET on Wednesday Mar 08, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oragenics Inc | 6.5M | -23.5x | --- |
Silo Pharma Inc | 6.6M | -1.3x | --- |
Phio Pharmaceuticals Corp | 6.5M | -0.6x | --- |
Panbela Therapeutics Inc | 6.5M | 0.0x | --- |
X T L Biopharmaceuticals Ltd | 6.4M | -5.3x | --- |
Creative Medical Technology Holdings Inc | 7.0M | -0.3x | --- |
Company Information
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. The Company's lead product, NT-CoV2-1, is an intranasal immunization vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its other product candidates include Terra CoV-2 and Antibiotics. Terra CoV-2 is an intramuscular vaccine candidate (plasmid + adjuvant) to provide long-lasting immunity against SARS-CoV-2. Antibiotics is a semi-synthetic analogs of MU1140, which is a member of lantibiotic class of antibiotics. The Company, through its wholly owned subsidiary, Noachis Terra, Inc. (Noachis Terra), is engaged in the research and development of its Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram negative infections.
Contact Information
- Headquarters
- SUITE 125, 4902 EISENHOWER BLVDTAMPA, FL, United States 33634
- Phone
- 813-286-7900
- Fax
- 813-286-7904
Executives
- Chairman of the Board
- Charles Pope
- President, Chief Executive Officer, Director
- Kimberly Murphy
- Chief Financial Officer, Treasurer, Secretary
- Janet Huffman
- Senior Vice President Discovery Research
- Martin Handfield
- Independent Director
- Alan Dunton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.5M |
|---|---|
Revenue (TTM) | $218.5K |
Shares Outstanding | 2.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $-0.14 |
Book Value | $0.23 |
P/E Ratio | -23.5x |
Price/Sales (TTM) | 29.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,485.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
